News

Applied Clinical Trials Online2h
FDA Review Changes and the Impact on Trial Design
In this video interview, Meri Beckwith, Co-CEO of Lindus Health, discusses recent Complete Response Letters issued to Replimune and Capricor, explaining how shifts in FDA reviewers can affect ...
Capricor Therapeutics Inc (CAPR) Q2 2025 Earnings Call Highlights: Navigating Challenges with ...
Despite zero revenue and increased losses, Capricor Therapeutics Inc (CAPR) focuses on strategic initiatives and regulatory ...
The Boston Globe12h
FDA regulator’s reinstatement sends biotech shares tumbling
Cambridge-based Sarepta Therapeutics Inc. stock dropped 1.6 percent in Monday trading. Capricor Therapeutics Inc. fell 13.8 percent and Replimune Group Inc. was down 5.7 percent. Prasad left the ...
Capricor Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update
Type A meeting with U.S. FDA scheduled to discuss Deramiocel BLA and path toward potential approvalCapricor seeks to resubmit ...
The Manila Times16h
Metagenomi Appoints Laurence Reid, PhD to its Board of Directors
Dr. Reid brings 30 years of experience in building biotech companies based on innovative scientific platforms and shaping ...
Capricor Therapeutics Announces Type A Meeting Scheduled with U.S. FDA
Detailed price information for Capricor Therap (CAPR-Q) from The Globe and Mail including charting and trades.
Levi & Korsinsky Notifies Capricor Therapeutics, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - CAPR
Detailed price information for Capricor Therap (CAPR-Q) from The Globe and Mail including charting and trades.
Vinay Prasad’s Return to FDA Sends Biotech Shares Tumbling
The shares of biotech companies fell after news that ousted regulator Vinay Prasad is set to go back to the US Food and Drug Administration.